NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework (Supply)
- Duration
- 2.5 year (est.)
- Value
- £296M
- Sector
- HEALTH
- Published
- 26 Feb 2024
- Delivery
- 01 Mar 2024 to 31 Aug 2026 (est.)
- Deadline
- n/a
Concepts
Location
Please refer to Document No. 10 in the ITO Documents for the list of Purchasing Points
Geochart for 2 buyers and 74 suppliers
2 buyers
- NHS England Leeds
38 suppliers
- Celltrion Healthcare Slough
- Biogen Berkshire
- Neon Healthcare Hertfordshire
- Pfizer Kent
- Bayer Reading
- Sandoz Surrey
- Aventis Pharma Berkshire
- Mylan Hatfield
- Merck Serono Middlesex
- Janssen Cilag Highwycombe
- Eli Lilly Hampshire
- Roche Products Welwyn Garden City
- Ipsen Slough
- Napp Pharmaceuticals Cambridge
- CST Pharma Walsall
- Orifarm Hertfordshire
- Teva Castleford
- Novo Nordisk West Sussex
- Novartis Pharmaceuticals London
- Zentiva Pharma London
- Glaxosmithkline London
- Merck Sharpe & Dohme London
- Accord Devon
- Drreddys Laboratories Cambridge
- Sun Pharma Uxbridge
- Sobi Swedish Orphan Biovitrum Cambridgeshire
- Galapagos Biotech Cambridge Cambridgeshire
- Thornton & Ross Huddersfield
- Astrazeneca London
- Almirall Uxbridge
- Gedeon Richter London
- Amgen Cambridge
- Vifor Pharma London
- Chugai Pharma London
- Abbvie Berks
- Merz Hemel Hempstead
- Pharmacosmos Berkshire
- Organon Pharmaceuticals London
Description
Project Title: NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024 Offer reference number: CM/PHR/22/5678 CM/PHR/22/5678/01 - NHS Framework for NORTH OF ENGLAND Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/22/5678/02 - NHS Framework for NORTH OF ENGLAND Branded Medicines (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 monthsCM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months
Lot Division
| 1 | CM/PHR/22/5678/01 CM/PHR/22/5678/01 - NHS Framework for North of England Branded Medicines - Tranche B. Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. |
| 2 | CM/PHR/22/5678/02 NHS Framework for North of England Branded Medicines - Lot 2. (to transition to Tranche B) Period of framework: 1 March 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. |
| 3 | CM/PHR/22/5678/03 CM/PHR/22/5678/03 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines - Tranche A. Period of framework: 1 March 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months |
| 4 | CM/PHR/22/5678/04 CM/PHR/22/5678/04 - NHS Framework for MIDLANDS AND EAST of England Branded Medicines (to transition to Tranche B). |
Award Detail
| 1 | Celltrion Healthcare (Slough)
|
| 2 | Biogen (Berkshire)
|
| 3 | Neon Healthcare (Hertfordshire)
|
| 4 | Pfizer (Kent)
|
| 5 | Bayer (Reading)
|
| 6 | Sandoz (Surrey)
|
| 7 | Aventis Pharma (Berkshire)
|
| 8 | Mylan (Hatfield)
|
| 9 | Merck Serono (Middlesex)
|
| 10 | Janssen Cilag (Highwycombe)
|
| 11 | Eli Lilly (Hampshire)
|
| 12 | Roche Products (Welwyn Garden City)
|
| 13 | Ipsen (Slough)
|
| 14 | Napp Pharmaceuticals (Cambridge)
|
| 15 | CST Pharma (Walsall)
|
| 16 | Orifarm (Hertfordshire)
|
| 17 | Teva (Castleford)
|
| 18 | Novo Nordisk (West Sussex)
|
| 19 | Novartis Pharmaceuticals (London)
|
| 20 | Zentiva Pharma (London)
|
| 21 | Glaxosmithkline (London)
|
| 22 | Celltrion Healthcare (Slough)
|
| 23 | Merck Sharpe & Dohme (London)
|
| 24 | Accord (Devon)
|
| 25 | Drreddys Laboratories (Cambridge)
|
| 26 | Pfizer (Kent)
|
| 27 | Aventis Pharma (Berkshire)
|
| 28 | Sun Pharma (Uxbridge)
|
| 29 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
| 30 | Galapagos Biotech (Cambridge Cambridgeshire)
|
| 31 | Thornton & Ross (Huddersfield)
|
| 32 | Astrazeneca (London)
|
| 33 | Janssen Cilag (Highwycombe)
|
| 34 | Eli Lilly (Hampshire)
|
| 35 | Roche Products (Welwyn Garden City)
|
| 36 | Almirall (Uxbridge)
|
| 37 | Orifarm (Hertfordshire)
|
| 38 | Teva (Castleford)
|
| 39 | Novartis Pharmaceuticals (London)
|
| 40 | Gedeon Richter (London)
|
| 41 | Amgen (Cambridge)
|
| 42 | Accord (Devon)
|
| 43 | Pfizer (Kent)
|
| 44 | Sandoz (Surrey)
|
| 45 | Vifor Pharma (London)
|
| 46 | Chugai Pharma (London)
|
| 47 | Abbvie (Berks)
|
| 48 | Merck Serono (Middlesex)
|
| 49 | Janssen Cilag (Highwycombe)
|
| 50 | Roche Products (Welwyn Garden City)
|
| 51 | Ipsen (Slough)
|
| 52 | Merz (Hemel Hempstead)
|
| 53 | Napp Pharmaceuticals (Cambridge)
|
| 54 | Pharmacosmos (Berkshire)
|
| 55 | Zentiva Pharma (London)
|
| 56 | Glaxosmithkline (London)
|
| 57 | Celltrion Healthcare (Slough)
|
| 58 | Merck Sharpe & Dohme (London)
|
| 59 | Accord (Devon)
|
| 60 | Drreddys Laboratories (Cambridge)
|
| 61 | Pfizer (Kent)
|
| 62 | Aventis Pharma (Berkshire)
|
| 63 | Sobi Swedish Orphan Biovitrum (Cambridgeshire)
|
| 64 | Galapagos Biotech (Cambridge Cambridgeshire)
|
| 65 | Thornton & Ross (Huddersfield)
|
| 66 | Astrazeneca (London)
|
| 67 | Janssen Cilag (Highwycombe)
|
| 68 | Eli Lilly (Hampshire)
|
| 69 | Roche Products (Welwyn Garden City)
|
| 70 | Organon Pharmaceuticals (London)
|
| 71 | Orifarm (Hertfordshire)
|
| 72 | Teva (Castleford)
|
| 73 | Novartis Pharmaceuticals (London)
|
| 74 | Gedeon Richter (London)
|
Award Criteria
| PRICE | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
- Award on basis of price.
Other Information
Price is not the only award criterion and all criteria are stated only in the procurement documents Please note that Lot 1 was also awarded to Kent Pharma Ltd in addition to those listed under the awarded suppliers below
Reference
- FTS 006097-2024